Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With Herpes Zoster Recombinant Subunit (HZ/su) Vaccine in Adults Aged 50 Years and Older

NCT05966090 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05966090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05966090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With Herpes Zoster Recombinant Subunit (HZ/su) Vaccine in Adults Aged 50 Years and Older
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
July 28, 2023
Completion date
July 29, 2024
Enrollment
530 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus infections, respiratory syncytial viruses